Ranitidine induces inhibition and structural changes in sucrase

J Enzyme Inhib Med Chem. 2012 Aug;27(4):553-7. doi: 10.3109/14756366.2011.601414. Epub 2011 Aug 18.

Abstract

Ranitidine is an antagonist of histamine-2 (H(2)) receptor. It is employed to treat peptic ulcer and other conditions in which gastric acidity must be reduced. Sucrase is a hydrolytic enzyme that catalyzes the breakdown of sucrose to its monomer content. A liquid of yeast sucrase was developed for treatment of congenital sucrase-isomaltase deficiency (CSID) in human. In this study, the effect of ranitidine on yeast sucrase activity was investigated. Our results showed that ranitidine binds to sucrase and inhibits the enzyme in a noncompetitive manner. The K(i) and IC(50) values were measured to be about 2.3 and 2.2 mM, respectively. Fluorescence measurement showed conformational changes after binding of ranitidine to the enzyme. The fluorescence spectra showed that ranitidine could bind to both free enzyme and enzyme-substrate complex, which was accompanied with reduction of emission intensity and red shift production.

MeSH terms

  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology*
  • Protein Conformation / drug effects
  • Ranitidine / chemistry
  • Ranitidine / pharmacology*
  • Saccharomyces cerevisiae / enzymology
  • Structure-Activity Relationship
  • Sucrase / antagonists & inhibitors*
  • Sucrase / chemistry*
  • Sucrase / metabolism

Substances

  • Enzyme Inhibitors
  • Ranitidine
  • Sucrase